Value
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 3.0 |
| P/S | 0.0 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 4.9 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 25.7x
- ▸PEG: 0.47
LGND · Why this verdict
Why Ligand Pharmaceuticals Incorpor (LGND) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Ligand is a high-quality pharmaceutical royalty franchise with a wide economic moat, elite margins, and a strong multi-quarter earnings track record, but the stock has reached its analyst price target leaving just 0.2% of upside at current levels — and a high-severity single-supplier dependency creates a meaningful concentration risk that warrants patience before adding exposure.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business carries a wide economic moat, sustains gross margins of 56%, and scores 66 on the Rule of 40 — a level the data characterizes as elite — signaling the company can generate high returns and grow simultaneously across multiple market cycles. Quality breakdown | Gross margin holds above 50% and the Rule-of-40 metric remains above 55 for four consecutive quarters, confirming structural franchise strength. | →Stable |
| CounterThe most recent quarter delivered an EPS miss of roughly 10%, showing even a wide-moat franchise can face execution disruptions; if that miss reflects something systematic rather than one-off, the quality narrative may need to be reassessed. | ||
The stock is trading within 0.2% of its take-profit target, effectively at the analyst price objective — meaning there is no remaining reward at the current price level, and the setup has been downgraded from a buy-wait posture for this reason. Warnings | A price pullback of at least 8% from current levels creates enough room between the stock price and the target to justify fresh evaluation. | ↑Improving |
| CounterMomentum is strong — MACD is bullish, on-balance volume is accumulating, and the stock is above its 200-day moving average — so the price may push through the current target if analyst consensus is revised upward. | ||
The company carries a high-severity single-supplier concentration for critical manufacturing inputs, meaning any disruption to that sole-source partner would be difficult to replace quickly and could materially impair revenue delivery. Risk breakdown | The company discloses at least one additional qualified manufacturing partner for sole-sourced inputs in an SEC filing within twelve months, reducing single-source dependency. | ↑Improving |
| CounterA deliberate sole-source manufacturing arrangement can enable tighter quality control and cost discipline; the concentration may represent a strategic choice rather than a vulnerability if the partner relationship is contractually protected. | ||
Three of the four most recent quarters produced large EPS beats averaging 36% in positive surprise, but the most recent quarter missed by roughly 10% — introducing uncertainty about whether the beat streak will resume. Earnings | EPS beats resume in each of the next two reported quarters with a positive surprise above 5%, reestablishing the historical cadence. | ↓Deteriorating |
| CounterThe three prior beats were exceptionally large, and a single 10% miss after three outsized quarters is consistent with a one-time item rather than a change in underlying earnings power — the baseline for a sustained beat streak may still be intact. | ||
The business carries a wide economic moat, sustains gross margins of 56%, and scores 66 on the Rule of 40 — a level the data characterizes as elite — signaling the company can generate high returns and grow simultaneously across multiple market cycles.
→StableQuality breakdown
- Expectation
- Gross margin holds above 50% and the Rule-of-40 metric remains above 55 for four consecutive quarters, confirming structural franchise strength.
CounterThe most recent quarter delivered an EPS miss of roughly 10%, showing even a wide-moat franchise can face execution disruptions; if that miss reflects something systematic rather than one-off, the quality narrative may need to be reassessed.
The stock is trading within 0.2% of its take-profit target, effectively at the analyst price objective — meaning there is no remaining reward at the current price level, and the setup has been downgraded from a buy-wait posture for this reason.
↑ImprovingWarnings
- Expectation
- A price pullback of at least 8% from current levels creates enough room between the stock price and the target to justify fresh evaluation.
CounterMomentum is strong — MACD is bullish, on-balance volume is accumulating, and the stock is above its 200-day moving average — so the price may push through the current target if analyst consensus is revised upward.
The company carries a high-severity single-supplier concentration for critical manufacturing inputs, meaning any disruption to that sole-source partner would be difficult to replace quickly and could materially impair revenue delivery.
↑ImprovingRisk breakdown
- Expectation
- The company discloses at least one additional qualified manufacturing partner for sole-sourced inputs in an SEC filing within twelve months, reducing single-source dependency.
CounterA deliberate sole-source manufacturing arrangement can enable tighter quality control and cost discipline; the concentration may represent a strategic choice rather than a vulnerability if the partner relationship is contractually protected.
Three of the four most recent quarters produced large EPS beats averaging 36% in positive surprise, but the most recent quarter missed by roughly 10% — introducing uncertainty about whether the beat streak will resume.
↓DeterioratingEarnings
- Expectation
- EPS beats resume in each of the next two reported quarters with a positive surprise above 5%, reestablishing the historical cadence.
CounterThe three prior beats were exceptionally large, and a single 10% miss after three outsized quarters is consistent with a one-time item rather than a change in underlying earnings power — the baseline for a sustained beat streak may still be intact.
Per-dimension breakdown
Quality
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 5.7 |
| ROA | 3.5 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 6.6 |
| Moat | 7.6 |
| Rule of 40 | 9.5 |
| Piotroski F | 8.9 |
- ▸Strong margins: 56%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Rule of 40: 66 (elite)
Growth
8.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.0 |
| EPS growth | 10.0 |
Momentum
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.6 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Uptrend pullback (RSI 39) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 9.0 |
| Analyst rating | 8.2 |
| Price target | 5.9 |
- ▸LLM news sentiment: +0.80 (n=1)
- ▸Light analyst coverage (10.0) — signal dampened
Insider
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Notable insider selling — $9,019,252 (0.148% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.6 |
| quality rank | 9.0 |
| growth rank | 5.0 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.1 |
| support resistance | 5.5 |
| 52w position | 8.6 |
| gap | 6.0 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 6.4 |
| volatility | 3.6 |
| put call | 7.9 |
| implied vol | 4.9 |
| beta | 7.1 |
| debt equity | 8.2 |
- ▸Concentration risks: 1 HIGH, 2 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.47, quality 7.7/10, growth 8.0/10).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|ENTRY_STICKY:PRIOR_STILL_VIABLEPassed (4)
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.80
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.9<4.5
- ASYMMETRY:-1.1=NEGATIVE
Warning (2)
- 8K_FLAG:1.02
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
-1.07
Upside
-7.6%
Downside
7.1%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeTemporary headwind — High quality (7.7) with weak momentum (2.9)
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The C-path quality+growth combination triggered the STRONG_BUY_WAIT verdict: quality 7.7 and growth 8.0 both clear their thresholds, with asymmetric R:R of -1.07 supporting the read.
The strongest dimensions are Growth at 8.0, Sentiment at 7.8, and Quality at 7.7; the weakest are Momentum at 2.9, Value at 4.2, and Peer rank at 4.7. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of -1.07 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Elite Quality
Trip ifGross margin compresses below 45% for 2 consecutive quarters.
- P2Price At Take Profit No Upside
Trip ifStock price declines more than 8% from current levels ($253.25), widening upside to the take-profit level beyond 8%.
- P3Single Supplier Concentration Risk
Trip ifCompany discloses at least 1 additional qualified manufacturing partner for sole-sourced inputs in an SEC filing within 12 months, reducing single-source dependency.
- P4Earnings Mostly Beating Recent Miss
Trip ifEPS surprise exceeds 5% for both of the next 2 consecutive reported quarters, reconfirming the beat pattern.